Literature DB >> 11904160

The P2X(7) receptor from Xenopus laevis: formation of a large pore in Xenopus oocytes.

Martin Paukert1, Susanti Hidayat, Stefan Gründer.   

Abstract

The purinergic P2X(7) receptor is an ATP-receptor channel predominantly expressed in immune cells. P2X(7) has been cloned from human, rat and mouse. Here we report cloning of the Xenopus laevis P2X(7) receptor (xP2X(7)). xP2X(7) is only about 50% identical to the mammalian homologues, shows a broad tissue expression pattern, and has the electrophysiological characteristics typical of a P2X(7) receptor: low agonist affinity (EC(50) about 2.6 mM) and a non-desensitizing current. Moreover, expression of xP2X(7) in Xenopus oocytes is sufficient to induce the formation of a large pore, which is permeable to large cations such as NMDG(+). Identification of a non-mammalian P2X(7) receptor may help to identify functionally important parts of the protein.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11904160     DOI: 10.1016/s0014-5793(02)02324-4

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  13 in total

Review 1.  Molecular and functional properties of P2X receptors--recent progress and persisting challenges.

Authors:  Karina Kaczmarek-Hájek; Eva Lörinczi; Ralf Hausmann; Annette Nicke
Journal:  Purinergic Signal       Date:  2012-05-01       Impact factor: 3.765

2.  Quantifying Ca2+ current and permeability in ATP-gated P2X7 receptors.

Authors:  Xin Liang; Damien S K Samways; Kyle Wolf; Elizabeth A Bowles; Jennifer P Richards; Jonathan Bruno; Sébastien Dutertre; Richard J DiPaolo; Terrance M Egan
Journal:  J Biol Chem       Date:  2015-02-02       Impact factor: 5.157

3.  A conserved MRF4 promoter drives transgenic expression in Xenopus embryonic somites and adult muscle.

Authors:  Timothy J Hinterberger
Journal:  Int J Dev Biol       Date:  2010       Impact factor: 2.203

4.  Homodimeric anoctamin-1, but not homodimeric anoctamin-6, is activated by calcium increases mediated by the P2Y1 and P2X7 receptors.

Authors:  Michaela Stolz; Manuela Klapperstück; Thomas Kendzierski; Silvia Detro-Dassen; Anna Panning; Günther Schmalzing; Fritz Markwardt
Journal:  Pflugers Arch       Date:  2015-01-17       Impact factor: 3.657

5.  P2X7 receptor in epilepsy; role in pathophysiology and potential targeting for seizure control.

Authors:  Tobias Engel; Alba Jimenez-Pacheco; Maria Teresa Miras-Portugal; Miguel Diaz-Hernandez; David C Henshall
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2012-12-26

6.  Bradykinin increases resensitization of purinergic receptor signaling in glioma cells.

Authors:  Héctor E López-Valdés; Luis Beltran-Parrazal; Kevin C Brennan; Andrew C Charles
Journal:  Cancer Cell Int       Date:  2010-09-27       Impact factor: 5.722

7.  Patch-clamp coordinated spectroscopy shows P2X2 receptor permeability dynamics require cytosolic domain rearrangements but not Panx-1 channels.

Authors:  Severine Chaumont; Baljit S Khakh
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-08       Impact factor: 11.205

8.  A functional P2X7 splice variant with an alternative transmembrane domain 1 escapes gene inactivation in P2X7 knock-out mice.

Authors:  Annette Nicke; Yung-Hui Kuan; Marianela Masin; Jürgen Rettinger; Benjamin Marquez-Klaka; Olaf Bender; Dariusz C Górecki; Ruth D Murrell-Lagnado; Florentina Soto
Journal:  J Biol Chem       Date:  2009-06-22       Impact factor: 5.157

9.  Pharmacological properties of the rhesus macaque monkey P2X7 receptor.

Authors:  Helen J Bradley; Liam E Browne; Wei Yang; Lin-Hua Jiang
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

10.  Insights into the Molecular Mechanisms Underlying Mammalian P2X7 Receptor Functions and Contributions in Diseases, Revealed by Structural Modeling and Single Nucleotide Polymorphisms.

Authors:  Lin-Hua Jiang; Jocelyn M Baldwin; Sebastien Roger; Stephen A Baldwin
Journal:  Front Pharmacol       Date:  2013-05-07       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.